These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 35599496)

  • 1. Effects of Gut Microbiota Alterations on Motor, Gastrointestinal, and Behavioral Phenotype in a Mouse Model of Parkinson's Disease.
    Radisavljevic N; Cirstea M; Bauer K; Lo C; Metcalfe-Roach A; Bozorgmehr T; Bar-Yoseph H; Brett Finlay B
    J Parkinsons Dis; 2022; 12(5):1479-1495. PubMed ID: 35599496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microbiota-mediated effects of Parkinson's disease medications on Parkinsonian non-motor symptoms in male transgenic mice.
    Radisavljevic N; Metcalfe-Roach A; Cirstea M; Tabusi MM; Bozorgmehr T; Bar-Yoseph H; Finlay BB
    mSphere; 2024 Jan; 9(1):e0037923. PubMed ID: 38078745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Dysbiosis and Dampened Gut Microbe Oscillation Precede Motor Dysfunction and Neuropathology in Animal Models of Parkinson's Disease.
    Liang F; Chen CY; Li YP; Ke YC; Ho EP; Jeng CF; Lin CH; Chen SK
    J Parkinsons Dis; 2022; 12(8):2423-2440. PubMed ID: 36155528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intestinal Pathology and Gut Microbiota Alterations in a Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Mouse Model of Parkinson's Disease.
    Lai F; Jiang R; Xie W; Liu X; Tang Y; Xiao H; Gao J; Jia Y; Bai Q
    Neurochem Res; 2018 Oct; 43(10):1986-1999. PubMed ID: 30171422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of gut microbiota in regulating gastrointestinal dysfunction and motor symptoms in a mouse model of Parkinson's disease.
    Bhattarai Y; Si J; Pu M; Ross OA; McLean PJ; Till L; Moor W; Grover M; Kandimalla KK; Margolis KG; Farrugia G; Kashyap PC
    Gut Microbes; 2021 Jan; 13(1):1866974. PubMed ID: 33459114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis.
    Zhao Z; Ning J; Bao XQ; Shang M; Ma J; Li G; Zhang D
    Microbiome; 2021 Nov; 9(1):226. PubMed ID: 34784980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated multi-omics profiling highlights the benefits of resveratrol hydroxypropyl-β-cyclodextrin inclusion complex for A53T transgenic mice through the microbiota-gut-brain axis.
    Sun X; Feng S; Qin B; Ye J; Xie L; Gui J; Sang M
    Food Funct; 2024 Feb; 15(3):1489-1512. PubMed ID: 38227477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MitoPark transgenic mouse model recapitulates the gastrointestinal dysfunction and gut-microbiome changes of Parkinson's disease.
    Ghaisas S; Langley MR; Palanisamy BN; Dutta S; Narayanaswamy K; Plummer PJ; Sarkar S; Ay M; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    Neurotoxicology; 2019 Dec; 75():186-199. PubMed ID: 31505196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease.
    Cui C; Han Y; Li H; Yu H; Zhang B; Li G
    Front Cell Infect Microbiol; 2022; 12():887407. PubMed ID: 36034698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson's disease.
    Hou YF; Shan C; Zhuang SY; Zhuang QQ; Ghosh A; Zhu KC; Kong XK; Wang SM; Gong YL; Yang YY; Tao B; Sun LH; Zhao HY; Guo XZ; Wang WQ; Ning G; Gu YY; Li ST; Liu JM
    Microbiome; 2021 Jan; 9(1):34. PubMed ID: 33517890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations of the gut microbiota with antibiotics protects dopamine neuron loss and improve motor deficits in a pharmacological rodent model of Parkinson's disease.
    Koutzoumis DN; Vergara M; Pino J; Buddendorff J; Khoshbouei H; Mandel RJ; Torres GE
    Exp Neurol; 2020 Mar; 325():113159. PubMed ID: 31843492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic stress-induced gut dysfunction exacerbates Parkinson's disease phenotype and pathology in a rotenone-induced mouse model of Parkinson's disease.
    Dodiya HB; Forsyth CB; Voigt RM; Engen PA; Patel J; Shaikh M; Green SJ; Naqib A; Roy A; Kordower JH; Pahan K; Shannon KM; Keshavarzian A
    Neurobiol Dis; 2020 Feb; 135():104352. PubMed ID: 30579705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-α signaling pathway.
    Sun MF; Zhu YL; Zhou ZL; Jia XB; Xu YD; Yang Q; Cui C; Shen YQ
    Brain Behav Immun; 2018 May; 70():48-60. PubMed ID: 29471030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probiotic Clostridium butyricum ameliorated motor deficits in a mouse model of Parkinson's disease via gut microbiota-GLP-1 pathway.
    Sun J; Li H; Jin Y; Yu J; Mao S; Su KP; Ling Z; Liu J
    Brain Behav Immun; 2021 Jan; 91():703-715. PubMed ID: 33148438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electroacupuncture may alleviate behavioral defects via modulation of gut microbiota in a mouse model of Parkinson's disease.
    Han QQ; Fu Y; Le JM; Pilot A; Cheng S; Chen PQ; Wu H; Wan GQ; Gu XF
    Acupunct Med; 2021 Oct; 39(5):501-511. PubMed ID: 33557583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Pilot Microbiota Study in Parkinson's Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models.
    Vidal-Martinez G; Chin B; Camarillo C; Herrera GV; Yang B; Sarosiek I; Perez RG
    J Parkinsons Dis; 2020; 10(1):185-192. PubMed ID: 31561385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor 21 ameliorates behavior deficits in Parkinson's disease mouse model via modulating gut microbiota and metabolic homeostasis.
    Yang C; Wang W; Deng P; Wang X; Zhu L; Zhao L; Li C; Gao H
    CNS Neurosci Ther; 2023 Dec; 29(12):3815-3828. PubMed ID: 37334756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fiber deprivation and microbiome-borne curli shift gut bacterial populations and accelerate disease in a mouse model of Parkinson's disease.
    Schmit KJ; Garcia P; Sciortino A; Aho VTE; Pardo Rodriguez B; Thomas MH; Gérardy JJ; Bastero Acha I; Halder R; Cialini C; Heurtaux T; Ostahi I; Busi SB; Grandmougin L; Lowndes T; Singh Y; Martens EC; Mittelbronn M; Buttini M; Wilmes P
    Cell Rep; 2023 Sep; 42(9):113071. PubMed ID: 37676767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rifaximin Modifies Gut Microbiota and Attenuates Inflammation in Parkinson's Disease: Preclinical and Clinical Studies.
    Hong CT; Chan L; Chen KY; Lee HH; Huang LK; Yang YSH; Liu YR; Hu CJ
    Cells; 2022 Nov; 11(21):. PubMed ID: 36359864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal dysfunction in Parkinson's disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation.
    Metta V; Leta V; Mrudula KR; Prashanth LK; Goyal V; Borgohain R; Chung-Faye G; Chaudhuri KR
    J Neurol; 2022 Mar; 269(3):1154-1163. PubMed ID: 33881598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.